The two most important products are an ointment (VDA-1102) for an early form of skin cancer and cutaneous T-cell lymphoma, and the active ingredient VDA-1275, which targets solid tumors and has shown strong synergistic effects with chemotherapeutic agents already on the market in preclinical studies. The Company's CEO is Prof. Max Herzberg, who is considered one of the founding fathers of the Israeli biotech industry. His charisma could help convince researchers from the US to join Vidac Pharma. Even Israel and the UK could attract bright minds. Both countries score highly with low regulation for researchers. BioNTech, for example, is deliberately pushing ahead with a cancer research program in the UK.
News & Events